CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating Activities:
Net income	$ 985	$ 12
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation expense	94	80
Amortization expense	546	445
Stock-based compensation expense	165	130
Acquired in-process research and development expenses	481	8
In-process research and development impairment	0	2,700
Deferred income taxes	(303)	(651)
Net loss from equity securities	256	96
Other	63	182
Changes in operating assets and liabilities:
Accounts receivable, net	635	699
Inventories	(227)	53
Prepaid expenses and other	26	(54)
Accounts payable	(272)	(91)
Income tax assets and liabilities, net	(161)	(112)
Accrued and other liabilities	(543)	(1,657)
Net cash provided by operating activities	1,744	1,840
Investing Activities:
Purchases of marketable debt securities	(527)	(613)
Proceeds from sales of marketable debt securities	167	119
Proceeds from maturities of marketable debt securities	324	506
Acquisitions, including in-process research and development, net of cash acquired	(551)	(807)
Purchases of equity securities	(125)	(28)
Capital expenditures	(109)	(247)
Other	(5)	0
Net cash used in investing activities	(826)	(1,070)
Financing Activities:
Proceeds from issuances of common stock	97	94
Repurchases of common stock under repurchase programs	(400)	(352)
Repayments of debt and other obligations	0	(500)
Payments of dividends	(969)	(945)
Other	(135)	(91)
Net cash used in financing activities	(1,406)	(1,794)
Effect of exchange rate changes on cash and cash equivalents	13	(18)
Net change in cash and cash equivalents	(476)	(1,042)
Cash and cash equivalents at beginning of period	5,412	5,338
Cash and cash equivalents at end of period	$ 4,936	$ 4,296